Literature DB >> 30154221

Association of Urinary Biomarkers of Kidney Injury with Estimated GFR Decline in HIV-Infected Individuals following Tenofovir Disoproxil Fumarate Initiation.

Simon B Ascher1,2, Rebecca Scherzer1, Michelle M Estrella1, William R Zhang1, Anthony N Muiru1, Vasantha Jotwani1, Carl Grunfeld1,3, Chirag R Parikh4, Deborah Gustafson5, Mary Young6, Anjali Sharma7, Mardge H Cohen8, Derek K Ng9, Frank J Palella10, Mallory D Witt11, Ken Ho12, Michael G Shlipak13,3.   

Abstract

BACKGROUND AND OBJECTIVES: Tenofovir disoproxil fumarate (tenofovir) is associated with elevated concentrations of biomarkers of kidney damage and dysfunction in individuals with HIV. The relationship of these kidney biomarkers with longitudinal kidney function decline is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We evaluated associations of 14 urinary biomarkers of kidney injury with changes in eGFR among 198 men and women with HIV who initiated tenofovir between 2009 and 2015 in the Multicenter AIDS Cohort Study and Women's Interagency HIV Study. Urinary biomarkers included albumin-to-creatinine ratio, α-1-microglobulin, β-2-microglobulin, cystatin C, kidney injury molecule-1 (KIM-1), IL-18, neutrophil gelatinase-associated lipocalin (NGAL), clusterin, osteopontin, uromodulin, monocyte chemoattractant protein-1, EGF, trefoil factor 3, and chitinase 3-like protein 1. We used multivariable linear mixed-effect models controlling for demographics, traditional kidney disease risk factors, and HIV-related risk factors to evaluate associations of baseline biomarkers with first-year changes in eGFR, and associations of year 1 and first-year change in biomarkers with changes in eGFR from year 1 to year 3. We used the least absolute shrinkage and selection operator method to identify a parsimonious set of biomarkers jointly associated with changes in eGFR.
RESULTS: Median eGFR before tenofovir initiation was 103 (interquartile range, 88-116) ml/min per 1.73 m2. During the first year of tenofovir use, eGFR decreased on average by 9.2 (95% confidence interval, 6.5 to 11.9) ml/min per 1.73 m2 and was stable afterward (decrease of 0.62; 95% confidence interval, -0.85 to 2.1 ml/min per 1.73 m2 per year). After multivariable adjustment, higher baseline β-2-microglobulin, KIM-1, and clusterin were associated with larger first-year eGFR declines, whereas higher baseline uromodulin was associated with a smaller eGFR decline. First-year increase in urinary cystatin C and higher year 1 IL-18 were associated with larger annual eGFR declines from year 1 to year 3. The parsimonious models identified higher pre-tenofovir clusterin and KIM-1, lower pre-tenofovir uromodulin, and higher year 1 IL-18 as jointly associated with larger eGFR declines.
CONCLUSIONS: Urinary biomarkers of kidney injury measured before and after tenofovir initiation are associated with subsequent changes in eGFR in individuals with HIV. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_08_28_CJASNPodcast_18_9_S.mp3.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Albumins; Biomarkers; Chemokine CCL2; Cohort Studies; Cystatin C; Demography; HIV; Hepatitis A Virus Cellular Receptor 1; Kidney injury; LCN2 protein, human; Lipocalin-2; Tenofovir; Tenofovir disoproxil fumarate; Uromodulin; creatinine; epidermal growth factor; glomerular filtration rate; interleukin 18 protein, human; risk factors

Mesh:

Substances:

Year:  2018        PMID: 30154221      PMCID: PMC6140559          DOI: 10.2215/CJN.01700218

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  32 in total

1.  Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury.

Authors:  Frank Dieterle; Elias Perentes; André Cordier; Daniel R Roth; Pablo Verdes; Olivier Grenet; Serafino Pantano; Pierre Moulin; Daniel Wahl; Andreas Mahl; Peter End; Frank Staedtler; François Legay; Kevin Carl; David Laurie; Salah-Dine Chibout; Jacky Vonderscher; Gérard Maurer
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

Review 2.  Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

Authors:  Ryan D Cooper; Natasha Wiebe; Nathaniel Smith; Philip Keiser; Saraladevi Naicker; Marcello Tonelli
Journal:  Clin Infect Dis       Date:  2010-09-01       Impact factor: 9.079

3.  Glomerular protein sieving and implications for renal failure in Fanconi syndrome.

Authors:  A G Norden; M Lapsley; P J Lee; C D Pusey; S J Scheinman; F W Tam; R V Thakker; R J Unwin; O Wrong
Journal:  Kidney Int       Date:  2001-11       Impact factor: 10.612

4.  Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.

Authors:  Hassane Izzedine; Jean Sebastien Hulot; Daniel Vittecoq; Joel E Gallant; Schlomo Staszewski; Vincent Launay-Vacher; Andrew Cheng; Gilbert Deray
Journal:  Nephrol Dial Transplant       Date:  2005-03-01       Impact factor: 5.992

5.  Tenofovir renal toxicity targets mitochondria of renal proximal tubules.

Authors:  James J Kohler; Seyed H Hosseini; Amy Hoying-Brandt; Elgin Green; David M Johnson; Rodney Russ; Dung Tran; C Michael Raper; Robert Santoianni; William Lewis
Journal:  Lab Invest       Date:  2009-03-09       Impact factor: 5.662

6.  Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1 alpha.

Authors:  Hai-Tao Yuan; Xiao-Zhong Li; Jolanta E Pitera; David A Long; Adrian S Woolf
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

7.  Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury.

Authors:  Won K Han; Veronique Bailly; Rekha Abichandani; Ravi Thadhani; Joseph V Bonventre
Journal:  Kidney Int       Date:  2002-07       Impact factor: 10.612

8.  Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.

Authors:  Ei Kinai; Hideji Hanabusa
Journal:  AIDS Res Hum Retroviruses       Date:  2009-04       Impact factor: 2.205

9.  Urinary interleukin-18 is a marker of human acute tubular necrosis.

Authors:  Chirag R Parikh; Alkesh Jani; Vyacheslav Y Melnikov; Sarah Faubel; Charles L Edelstein
Journal:  Am J Kidney Dis       Date:  2004-03       Impact factor: 8.860

10.  Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis.

Authors:  Ivica Grgic; Gabriela Campanholle; Vanesa Bijol; Chang Wang; Venkata S Sabbisetti; Takaharu Ichimura; Benjamin D Humphreys; Joseph V Bonventre
Journal:  Kidney Int       Date:  2012-03-21       Impact factor: 10.612

View more
  9 in total

1.  Renal injury and human immunodeficiency virus: what remains after 30 years?

Authors:  Sophie de Seigneux; Gregory M Lucas
Journal:  Nephrol Dial Transplant       Date:  2020-04-01       Impact factor: 5.992

Review 2.  Tenofovir nephrotoxicity among Asians living with HIV: review of the literature.

Authors:  Takeshi Nishijima; Hiroyuki Gatanaga; Shinichi Oka
Journal:  Glob Health Med       Date:  2019-12-31

3.  Association of Non-Steroidal Anti-Inflammatory Drugs with Kidney Health in Ambulatory Older Adults.

Authors:  Jonathan G Amatruda; Ronit Katz; Carmen A Peralta; Michelle M Estrella; Harini Sarathy; Linda F Fried; Anne B Newman; Chirag R Parikh; Joachim H Ix; Mark J Sarnak; Michael G Shlipak
Journal:  J Am Geriatr Soc       Date:  2020-12-10       Impact factor: 5.562

4.  Associations of CKD risk factors and longitudinal changes in urine biomarkers of kidney tubules among women living with HIV.

Authors:  Anthony N Muiru; Rebecca Scherzer; Simon B Ascher; Vasantha Jotwani; Carl Grunfeld; Judy Shigenaga; Kimberly A Spaulding; Derek K Ng; Deborah Gustafson; Amanda B Spence; Anjali Sharma; Mardge H Cohen; Chirag R Parikh; Joachim H Ix; Michelle M Estrella; Michael G Shlipak
Journal:  BMC Nephrol       Date:  2021-08-30       Impact factor: 2.585

5.  Tenofovir disoproxil fumarate initiation and changes in urinary biomarker concentrations among HIV-infected men and women.

Authors:  William R Zhang; Rebecca Scherzer; Michelle M Estrella; Simon B Ascher; Anthony Muiru; Vasantha Jotwani; Carl Grunfeld; Chirag R Parikh; Deborah Gustafson; Seble Kassaye; Anjali Sharma; Mardge Cohen; Phyllis C Tien; Derek K Ng; Frank J Palella; Mallory D Witt; Ken Ho; Michael G Shlipak
Journal:  AIDS       Date:  2019-03-15       Impact factor: 4.177

Review 6.  The Promise of Tubule Biomarkers in Kidney Disease: A Review.

Authors:  Joachim H Ix; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2021-05-27       Impact factor: 8.860

7.  Kidney tubule health scores and their associations with incident CKD in women living with HIV.

Authors:  S B Ascher; R Scherzer; M M Estrella; A N Muiru; V K Jotwani; C Grunfeld; J Shigenaga; K A Spaulding; D K Ng; D Gustafson; A B Spence; A Sharma; M H Cohen; C R Parikh; J H Ix; M G Shlipak
Journal:  HIV Med       Date:  2021-03-09       Impact factor: 3.094

8.  Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.

Authors:  Karla Cristina Silva Petruccelli; Djane Clarys Baía-da-Silva; Fernando Val; Monica Santos Valões; Nadia Cubas-Vega; Alexandre Vilhena Silva-Neto; Vanderson Sampaio; Aline Alencar; Roberto Pecoits-Filho; Rodrigo Carvalho Moreira; Sandra Wagner Cardoso; Ronaldo I Moreira; Iuri Costa Leite; José Valdez Madruga; Esper G Kallas; Paulo R Alencastro; Brenda Hoagland; Beatriz Grinsztejn; Valdiléa Gonçalves Veloso Santos; Marcus Vinícius Guimarães Lacerda
Journal:  AIDS Res Ther       Date:  2022-02-24       Impact factor: 2.250

9.  HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.

Authors:  Simon B Ascher; Rebecca Scherzer; Michelle M Estrella; Judy Shigenaga; Kimberly A Spaulding; David V Glidden; Megha L Mehrotra; Patricia Defechereux; Monica Gandhi; Robert M Grant; Michael G Shlipak; Vasantha Jotwani
Journal:  AIDS       Date:  2020-04-01       Impact factor: 4.632

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.